Australian Kalydeco decision 'deferred,' patients will fight but need a champion
This article was originally published in Scrip
Executive Summary
Cystic fibrosis patients in Australia have lost round one in their battle to get affordable access to Vertex's Kalydeco, after the government-appointed body in charge of granting treatments for reimbursement deferred making a decision on the drug because it is priced too high. Patients in Australia who are eligible for the drug, which is used to treat CF sufferers with the G551D gene, say they feel they have no one "championing" their fight.
You may also be interested in...
Cystic Fibrosis: Successes, Opportunities And Challenges
What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.